about
Drug interactions with angiotensin receptor blockers.Olmesartan medoxomil for the treatment of hypertension in children and adolescentsAntihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists.Olmesartan medoxomil: current status of its use in monotherapy.Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.Two selective HPTLC methods for determination of some angiotensin II receptor antagonists in tablets and biological fluids.Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.Mutagenic assessment of olmesartan cilexetil by bacterial mutation assay.Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy.Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.Using predrugs to optimize drug candidates.In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.Olmesartan for the treatment of arterial hypertension.Formulation and evaluation of liquisolid compacts for olmesartan medoxomil.Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology.Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.The angiotensin II receptor antagonist, losartan, enhances regulator of G protein signaling 2 mRNA expression in vascular smooth muscle cells of Wistar rats.Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
P2860
Q33211891-1049E479-9B5B-4321-847A-BC75FEB03BB0Q34772915-A97E03CE-E7D8-4C6E-9077-E307FB18CC11Q35688193-DA85AA8C-E6A9-461E-B48A-74080E83B539Q35868228-E44E0F08-5584-4C80-ACAA-5AAE6B15C7FFQ35905180-8A3EDFF9-122A-4F8E-B0AE-77105953FC5AQ36013054-C383EF6B-9852-4244-ABFF-7D42385E1584Q36160619-47FFC885-4271-4334-B815-77E1858A31E9Q36220469-45DD90C8-D059-4121-9C65-CE4A6B8B6FCBQ36503368-65E85F7F-788B-4C31-B8D0-0B7E450E298FQ37425252-32D1AF3D-1352-467D-8D56-312872A46233Q37910206-A4D689D7-8E56-46F2-A8D9-E4D39DF6D4C5Q38061463-2A80B8AD-7F9D-4C41-AA88-801EFFEC9208Q38243993-85297B95-79B0-4772-B0A4-EBDB097D685CQ38469693-956781F5-AF53-4522-87DE-F4B66614C1F9Q38548995-2512DE79-D6D9-414E-B853-22A1CE4EDC8EQ40076763-EFAF5632-54D9-4A5C-9E1E-A98176271690Q42920272-A628C5E5-6621-4DAB-A9AE-65433D0F1756Q43078099-59079205-4ECC-4743-A880-EACC04ECE04DQ46272614-CB91ABBE-63F9-445B-AFA9-7D5F3599CB89Q50094521-70EE674A-FABE-4071-A30C-32208111A016Q50892340-6EC3A6CD-D7A1-4DA8-A683-8D25959CCE63Q52899014-A801FAF0-1204-447C-8984-DCFCAD070783Q52929592-65D974E5-98CB-4C4E-93AF-1DB874D15E77Q53769446-9C0DD245-5CED-4659-ABA1-38E40823031CQ54530036-CD5010D2-1EA8-49B9-851B-0608778667EC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Olmesartan medoxomil.
@ast
Olmesartan medoxomil.
@en
Olmesartan medoxomil.
@nl
type
label
Olmesartan medoxomil.
@ast
Olmesartan medoxomil.
@en
Olmesartan medoxomil.
@nl
prefLabel
Olmesartan medoxomil.
@ast
Olmesartan medoxomil.
@en
Olmesartan medoxomil.
@nl
P1433
P1476
Olmesartan medoxomil.
@en
P2093
Blair Jarvis
Gregory T Warner
P304
1345-53; discussion 1354-6
P356
10.2165/00003495-200262090-00005
P577
2002-01-01T00:00:00Z
P6179
1043664368